\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average b | ourden | | | | | | | |

| Estimated average burden hours per response: | 0.5 |
|--|-----|
| | 0.0 |

| 1. Name and Addre | ess of Reporting Personners N JOHN | on [*] | 2. Issuer Name and Ticker or Trading Symbol <u>PHARMATHENE, INC</u> [PIP] | | ationship of Reporting Pe k all applicable) Director | rson(s) to Issuer 10% Owner |
|-----------------------|---------------------------------------|-----------------|--|-----------------------|---|--------------------------------|
| (Last) C/O PHARMA | | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 05/25/2011 | | Officer (give title below) | Other (specify below) |
| (Street) ANNAPOLIS | ACE, SUITE 450 | 21401 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indi Line) X | vidual or Joint/Group Filir Form filed by One Rep Form filed by More that Person | porting Person |
| | | (Zip) | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---|--|---|------------------------------|---|--|---------------|---|---|---|--------------------------------|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (11001 4) |
| Common Stock, \$0.0001 par value per share ⁽¹⁾ | 05/25/2011 | | s | | 50,000 | D | \$ 3.6827 ⁽²⁾ | 394,044 | Ι | See Footnote ⁽¹⁾ |
| Common Stock, \$0.0001 par value per share | | | | | | | | 911,164 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exerc Expiration Da (Month/Day/Y | nd 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---|---|--|---|------------------------------|---|-----|-----|--|--|-------|---|--|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. The shares reported in this row are owned by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of such shares, and this report shall not be deemed an admission that the reporting person was or is the beneficial owner of the shares for purposes of Section 13(d) or Section 16 of the Exchange Act or for any other purpose.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.65 to \$3.73, inclusive. The reporting person undertakes to provide to PharmAthene, Inc., any security holder of PharmAthene, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

/s/ Roland S. Chase, attorney in 05/27/2011

fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.